^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    S095025

    i
    Other names: S095025, PRS-352
    Associations

    News

    Trials
    Company:
    Pieris Pharmaceuticals, Servier
    Drug class:
    PD-L1 inhibitor, OX40 agonist
    Related drugs:
    Associations

    News

    Trials
    2years
    The anticalin-antibody bispecific PRS-352/S095025 strongly stimulates human CD4+ T cells in a PD-L1-dependent manner (AACR 2022)
    We provide here the preclinical characterization of the fusion protein PRS-352/S095025, a bispecific molecule composed of a PD-L1 blocking moiety and an Anticalin protein agonizing OX40. In vitro, this molecule showed the desired MoA, PD-L1 blocking and potent OX40 agonism driven by binding to PD-L1, with superior activity to a clinical stage OX40 agonist.
    Late-breaking abstract • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • TNFA (Tumor Necrosis Factor-Alpha) • CD4 (CD4 Molecule)
    |
    PD-L1 expression
    |
    S095025